Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring c-MET amplification.

A 72-year-old man with metastatic hepatocellular carcinoma (HCC) previously received first-line systemic therapy with atezolizumab plus bevacizumab. His disease was judged to be progressing 5 months after treatment initiation. Comprehensive genomic profiling (CGP) revealed cytoplasmic Mesenchymal Epithelial Transition factor amplification. On the basis of an expert panel's recommendation, he received cabozantinib as second-line therapy. The tumors shrank markedly and continued to shrink 6 months after treatment. CGP could provide useful information for selecting effective second-line treatments for patients with HCC after first-line immunotherapy. This article is protected by copyright. All rights reserved.